


PHARMACEUTICAL 2017

Dare Bioscience Inc. Rank 221 of 292









PHARMACEUTICAL 2017

Dare Bioscience Inc. Rank 221 of 292



The relative strengths and weaknesses of Dare Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dare Bioscience Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 35% points. The greatest weakness of Dare Bioscience Inc. is the variable Net Income, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is -54%, being 57% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	36,790
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,939
Liabilities, Non-Current	7,638
Other Assets	230
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-2,151
Other Revenues	766
Property and Equipment	668
Research and Development	27,565
Selling, General and Administrative Expense	10,355

Output Variable	Value in 1000 USD
Assets	37,688
Liabilities	24,577
Expenses	37,920
Revenues	766
Stockholders Equity	13,111
Net Income	-39,305
Comprehensive Net Income	-39,305
Economic Capital Ratio	-54%

